Jan zur Hausen, a principal shareholder of Bergmann zur Hausen & Cie GmbH, has been elected to the supervisory board of MagForce AG, a German medical device company in the field of nanomedicine. Dr zur Hausen has previously worked at Hoffmann-La Roche, MPM Capital, Mulligan BioCapital and DVC Deutsche Venture Capital. He has a degree in biology and a PhD in cell biology from the University of Basel in Switzerland.
MagForce AG announced the election on 17 August 2012.
Copyright 2012 Evernow Publishing Ltd